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 Introduction 
 Survival after premature birth is largely dependent 
upon the maturational stage of the lung. At approximate-
ly 25 weeks’ gestation, the lungs undergo an anatomical 
transition from the ‘canalicular’ to the ‘saccular’ stage  [1] . 
This is heralded by the differentiation of the cuboidal ep-
ithelial lining of the future airway spaces, and also by the 
enlargement of the pulmonary capillary bed which be-
gins to form extended contact with the future air spaces. 
From animal studies, it has long been known that reti-
noids have a profoundly stimulating effect on lung growth 
and maturation  [2] . This beneficial effect of retinoic acid 
(RA) is mainly true for the initial outgrowth, and for lat-
er alveogenesis, while in between, RA have been shown 
to rather inhibit branching morphogenesis. They have a 
true maturational effect on the lung epithelium. They 
also accelerate fetal lung branching, leading to the devel-
opment of the alveolar tree  [3] , and favor choline incor-
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 Abstract 
 The viability of the human fetus increases significantly be-
yond 25 weeks’ gestation as the lung development pro-
gresses towards the ‘saccular’ stage. We report on a fetus of 
22 weeks’ gestation whose lung maturation was accelerated 
by 4 weeks, most likely due to the unintentional exposure to 
the retinoid isotretinoin (13- cis -retinoic acid) during preg-
nancy. Although retinoids are known to be stored within the 
lungs and to play a key role in lung differentiation and 
growth, their storage within the lung is limited during this 
critical developmental period. Even though glucocorticoste-
roids are used clinically to enhance lung maturation in the 
face of impending preterm birth, there are no data yet which 
demonstrate that glucocorticosteroids, when given alone, 
are effective in promoting lung maturation prior to 24 weeks’ 
gestation. Strong evidence however, indicates that gluco-
corticosteroids promote the utilization of lung retinoids im-
mediately before birth. Our observation of increased lung 
maturation, in conjunction with the above information sug-
gests that retinoids alone or in combination with glucocor-
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poration into phosphatidylcholine  [4] . At present, the 
only widely accepted method to stimulate pulmonary 
maturation before preterm birth is through antenatal ad-
ministration of glucocorticosteroids to the mother. How-
ever, for this to be effective, birth must be postponed for 
at least 24–48 h, and there must be a sufficient number of 
type II pneumocytes as the main action of glucocortico-
steroids is to increase surfactant production, and not to 
promote further structural development. Another, less 
well known mechanism of action of steroids is to increase 
the utilization of lung retinyl palmitate stores and pro-
mote the consumption of retinol. Geevarghese and Chyt-
ill have shown that the depletion of pulmonary vitamin 
A stores before birth, which is necessary for lung differ-
entiation, is enhanced by administering dexamethasone 
 [5] . 
 Case Report 
 A 23-year-old woman began treatment  with isotretinoin 
(Roaccutan  , 30 mg daily) for severe acne. Two months later, she 
unknowingly became pregnant and it was not until 20 weeks’ ges-
tation that she consulted a physician. The probability of fetal mal-
formations was considered sufficient to recommend termination 
of pregnancy. An abortion was therefore induced at 22 weeks. The 
intake of isotretinoin was never discontinued. 
 The male fetus did not show any gross anomalies or malforma-
tions; body size measurements and organ weights were all within 
the normal range for gestational age. No signs of hydrocephalus 
and no external ear malformations were found. Special attention 
was paid to the brain which showed a gyration pattern and a neu-
ronal stratification corresponding to 22 weeks’ gestational age. 
Similarly, skin development also indicated that the fetus was not 
older than 22 weeks’ gestation  [6] . The only finding discordant to 
the gestational age of 22 weeks was a striking development accel-
eration in lung morphology. Normally in the human fetus at 22 
weeks, the future airways are lined with a cuboidal epithelium, 
and a capillary network is found on the stromal side of the epithe-
lial cells. In this so-called ‘canalicular’ stage, capillaries regularly 
extend between the epithelial cells and occasionally touch the lu-
minal space ( fig. 1 a). This fetus presented a pulmonary morphol-
ogy of both lower lung lobes which differed in several aspects 
from what is normally seen at 22 weeks. Cuboidal epithelial lining 
was only observed in a limited amount of subpleural lung tissue. 
Moreover, the capillary bed was well advanced as capillaries 
formed frequent and broad contact to the luminal space ( fig. 1 b). 
In summary, postmortem results demonstrated that the lungs of 
this fetus had reached a morphological stage of maturation (sac-
cular stage) that is usually seen at approximately 26 weeks’ gesta-
tion, while all other postmortem indications were in keeping with 
a gestational age of 22 weeks. 
 Fig. 1. Advanced maturation of the bron-
choalveolar tree (lower lung lobe).  a The 
typical canalicular stage of lung develop-
ment in a normal fetus at 22 weeks’ gesta-
tional age shows airways lined by a cuboi-
dal epithelium with a few capillaries reach-
ing the lumen.  b The lungs of a fetus with 
high maternal intake of isotretinoin re-
veals a saccular stage where capillaries 
have already formed frequent contacts to 
the lumen of many alveolar spaces, more 
in keeping with a gestational age of 26 
weeks. HE.  ! 250. 
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 Discussion 
 To our knowledge, this is the first  report of a human 
fetus whose lung maturation may have been significantly 
accelerated by unintentional exposure to isotretinoin. 
Our observation extends to the human the numerous 
earlier observations from in vitro and animal research 
that vitamin A compounds (retinoids) play a key role in 
lung differentiation, growth and healing  [3, 4, 7–10] . In 
the situation of some uncertainty regarding gestational 
age, we took great care not only to rely on body size mea-
surements and organ weights to assess gestational age as 
precisely as possible. We also used several accepted more 
reliable methods such as foot length, brain development 
and skin histology  [6] . Although a gestational age of 22 
weeks was estimated by these methods, the lung histol-
ogy of this fetus, assessed by 2 independent highly trained 
examiners, was in keeping with that of a more mature 26 
weeks’ gestation fetus. As the mammalian lung matura-
tion progresses from apical to basal, we routinely exam-
ine both lower lung lobes (central and peripheral areas) 
when trying to determine lung maturation. 
 Fetal lung development is accelerated by retinoids in 
both in vivo animal studies  [4] and in studies of cultured 
lung tissue  [11] . Retinoids are known to accelerate fetal 
lung branching leading to the development of the alveolar 
tree and also promote the expression of some genes cod-
ing for surfactant proteins and enzymes in the produc-
tion of their lipid component  [3] . It is not completely clear 
whether this acceleration effect is caused by a direct effect 
on epithelial differentiation, by interactions with mesen-
chymal cells  [12] , or in concert with mediators, i.e. inter-
leukins  [3] . 
 A major concern in recent years has centered around 
the teratogenic effects of very high doses of 13- cis -isotret-
inoin. A study on teratogenicity of high vitamin A intake 
( 1 10,000 IU/day) in over 22,000 pregnant women did not 
observe any birth defects when vitamin A supplementa-
tion was started after week 7  [13] . Korte et al. [14] found 
RA embryopathies in monkeys only when the exposition 
to 13- cis -RA occurred in the period preceding organo-
genesis. For the human being, this teratogenically sensi-
tive period occurs over 3–8 weeks after conception (cor-
responding approximately to gestational weeks 5–10) 
 [15] . As stated by Chytill, the teratogenical effects of high 
doses of retinoids during embryogenesis have overshad-
owed the key role that retinoids play in normal cellular 
differentiation during fetal life  [3] . 
 Not only have retinoids been shown to be importantly 
involved in the induction and regulation of alveogenesis, 
there is also increasing support for their possible thera-
peutic value in humans  [9] . Bronchopulmonary dyspla-
sia, one of the major long-term burdens of prematurity, 
presents in a classical form with inflammation, fibrosis 
and smooth muscle hypertrophy. More recently, bron-
chopulmonary dysplasia has also presented in a new form 
in extremely preterm infants born just when alveolariza-
tion of the distal lung saccules is beginning, which arrests 
alveolar and vascular development  [16, 17] . Both forms of 
bronchopulmonary dysplasia result in a lung deficient in 
alveoli, and therefore deficient in gas exchange area. Vi-
tamin A and its analogues have been proposed for the 
prevention and treatment of bronchopulmonary dyspla-
sia, and clinical trials have been conducted in premature-
ly delivered infants  [18] . As the storage of vitamin A and 
its compounds in the lungs occurs during the latter third 
of pregnancy  [19] , premature infants  ! 37 weeks’ gesta-
tion have limited vitamin A stores  [20, 21] . Several au-
thors have also shown that pulmonary vitamin A stores 
deplete shortly before birth  [4, 22] , indicating an in-
creased demand for retinoids in the crucial periods of 
lung differentiation. Moreover, postnatal glucocortico-
steroids may impact on lung development by inhibiting 
alveolarization  [10, 23] , and RA, a biologically active de-
rivative of vitamin A, has been shown in the animal mod-
el to block this inhibitory effect or to restore gas exchange 
area  [10, 24] . Whether histological regeneration of the al-
veoli also translates into a functional recovery still re-
mains to be elucidated  [25] . 
 Glucocorticosteroids are administered to a pregnant 
mother when in danger of delivering prematurely, and 
they increase surfactant production. Unfortunately glu-
cocorticosteroids only prevent respiratory distress syn-
drome in approximately 40–50% of cases  [26] , and re-
petitive courses seem not to be of further benefit  [27] . 
Another mechanism by which glucocorticosteroids pro-
mote lung maturation is an increased utilization of lung 
retinyl palmitate stores and the consumption of retinol, 
as shown by Geevarghese and Chytill  [5]  using dexa-
methasone. Similarly, steroids given antenatally to rhesus 
monkeys  [28] and pregnant women  [29] increased both 
maternal and fetal concentrations of retinol-binding pro-
tein, pointing to the critical link between steroidal effi-
cacy and retinoid utilization. 
 Our report of the documented intake of 30 mg/day of 
isotretinoin up to the day of delivery in a nonviable fetus 
of 22 weeks’ gestational age demonstrates that matura-
tion of the lungs in a human fetus may be strongly accel-
erated by retinoids at that early stage of gestation. This 
fetus demonstrated a spatial relationship of epithelium 
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and capillaries corresponding to a fetus of 26 weeks. 
There is no evidence that glucocorticosteroids are effec-
tive in promoting lung maturation before 24 weeks. How-
ever, given the links between glucocorticosteroids and 
retinoid compounds, a combined therapy of these agents 
might propel lung maturation more effectively than each 
compound in isolation when the clinician is faced with 
an impending premature birth at the limits of viability. 
The possible advantages of retinoids in lung differentia-
tion when applied in the days before preterm delivery 
when stores are low, and the potentially additive effects 
of glucocorticosteroids have not yet been extensively ex-
plored. 
 Although the information of our case report does not 
allow more firm conclusions, our observation provides 
the enticing prospect that RA, or its derivates may one 
day serve as a valuable preventive or therapeutic tool in 
cases of extreme prematurity. Before our observation can 
be translated into safe clinical reality for tiny preterm in-
fants, extensive research and development will be re-
quired to answer the many questions related to formula-
tion, efficacy and safety. 
